Importantly, GSK137831, an inhibitor of Nox1/4, has been passed through Phase 1 clinical trials (NCT02010242) for treatment of Type 2 Diabetes and Albuminuria, suggesting that GSK137831 may be used in the clinical treatment of activated osteoclastogenesis disease. The gene discussed is NOX1; the disease is type 2 diabetes mellitus.